Professor Raphael Mechoulam, also known as the “father of cannabis research,” revealed his latest discovery, cannabidiolic acid methyl ester (EPM301), only a few months ago. The introduction of this new, patented compound (synthetic, fully stable acid-based cannabinoid molecules) caused a wave of excitement around the future of medicinal cannabis. The compound in question was presented to the world in partnership with EPM, a global biotechnology company based in the U.S. that aims to bridge the gap between the cannabis and pharmaceutical industries. Comment: That sounds like a possibly ominous partnership. During a recent, exclusive conversation, CEO Reshef Swisa and Dr. Mechoulam, shared the history of the journey behind this revolutionary process and its significance in evolving the use of CBD as a pharmaceutical drug.